Alzinova Ab · OMXSTO:ALZ
Alzinova Ab — Investor Presentation (January 2022)
18 slides from Alzinova Ab's investor presentation, Jan 17, 2022
Slide 1: Alzinova – Company Presentation
Alzinova – Company Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate
Slide 3: Alzinova is developing the first oligomer-specific vaccine against Alzheimer’s disease
Alzinova is developing the first oligomer-specific vaccine against Alzheimer’s disease Swedish biopharma company Based in Gothenburg. Founded: 2011 High unmet medical need for Alzheimer’s disease Innovative science and proprietary technology enables development of disease-modifying treatments for Al
Slide 4: Alzheimer’s disease is a progressively debilitating disease with the highest unmet medical need
Alzheimer’s disease is a progressively debilitating disease with the highest unmet medical need >55 million patients have dementia, >130 million in 2050 Alzheimer’s = 60-80% of all dementia Impacts quality of life for patients, their families and care givers Annual cost of dementia US $1.3 trillion
Slide 5: Alzinova – product pipeline targeting Alzheimer’s Disease
Alzinova – product pipeline targeting Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Planned Milestone ALZ-1011) therapeutic H2 2023 Topline data vaccine clinical phase 1b ALZ-2012) monoclonal H1 2022 Decision on way antibody forward 1) Phase 1b study in patients with Al
Slide 6: Alzinova’s AβCC peptide technology enables development of high precision, disease-modifying therapies
Alzinova’s AβCC peptide™ technology enables development of high precision, disease-modifying therapies specifically targeting the neurotoxic oligomers 6 ©2022 Alzinova AB (publ), All rights reserved
Slide 7: New generation anti-amyloidβ immunotherapy
New generation anti-amyloidβ immunotherapy Non-specific binding Non-specific binding Specific binding Selectivity for aggregated Aβ Oligomer-specific targeting Aβ40 Aβ42 Toxic forms (oligomers) Insoluble Aβ forms (fibrils) Side effects (ARIA:s) Side effects (ARIA:s) Best in-class potential No clinic
Slide 8: Alzinova is developing two oligomer-specific products based on the same technology
Alzinova is developing two oligomer-specific products based on the same technology • ALZ-101 vaccine • ALZ-201 monoclonal antibody Advantages of therapeutic vaccines − High patient compliance (few booster doses) − Cost effective − Preventive treatment possible 8 ©2022 Alzinova AB (publ), All rights
Slide 9: ALZ-101 represents a potential breakthrough in Alzheimer's Disease
ALZ-101 represents a potential breakthrough in Alzheimer's Disease • Highly specific therapeutic vaccine, directed towards the neurotoxic oligomeric Aβ • Opportunity to become an effective and well tolerated treatment to halt and reverse Alzheimer’s • Best-in-class potential Immunotherapeutic drug c
Slide 10: Strong data supporting clinical development of ALZ-101
Strong data supporting clinical development of ALZ-101 Transgenic mice vaccinated with ALZ-101 • Comprehensive pre-clinical package showed a 25% increase of synapse density compared to controls – ALZ-101 is well tolerated in non-clinical toxicity studies ✓ – Efficacy data in three different models,
Slide 11: ALZ-101 Phase 1b clinical study in patients with Alzheimer’s disease
ALZ-101 Phase 1b clinical study in patients with Alzheimer’s disease 20-week study with four doses of ALZ-101/placebo on week 0, 4, 8 and 16 with follow-up period of 48 weeks ALZ-101 Endpoints: 125 μg N=10 Primary: safety, tolerability ALZ-101 Secondary: Immunogenicity 26 subjects R (Aβ-specific) wi
Slide 12: Development of vaccine ALZ-101 and monoclonal antibody ALZ-201 - a three-pronged approach
Development of vaccine ALZ-101 and monoclonal antibody ALZ-201 - a three-pronged approach ALZ-101 vaccine - phase 1b study • 1 year recruitment – ongoing ALZ-101 vaccine – phase 2 ready • Long-term extension study of phase 1b – planning • Process optimization of manufacturing of peptide (ALZ-101) –
Slide 13: Alzinova's business model: develop, document, prepare, partner
Alzinova's business model: develop, document, prepare, partner • Develop novel disease-modifying immunotherapies based on proprietary AβCC technology • Document safety and tolerability in patients with Alzheimer’s disease • Prepare (in parallel) for phase 2 to optimize the value of the candidates •
Slide 14: Experienced management team and innovation-focused collaborations
Experienced management team and innovation-focused collaborations Kristina Torfgård, PhD Anders Sandberg, PhD Anders Bylock, MD, PhD Chief Executive Officer Chief Scientific Officer and Chief Medical Officer Co-Founder >25 years experience – >30 years experience – AstraZeneca, Albireo >20 years expe
Slide 15: Board of Directors with extensive pharma and biopharma experience
Board of Directors with extensive pharma and biopharma experience Björn Larsson Anders Blom Per-Göran Gillberg, PhD Chair of the Board >25 years experience – 35 years in experience – >25 years experience – Pharmacia & Upjohn, Q-Med AB, Kabi, Kabi Pharmacia, Pharmacia & Novo Nordisk, AstraZeneca, Nex
Slide 16: Alzinova's portfolio represents a potential breakthrough for the treatment of Alzheimer’s patients
Alzinova's portfolio represents a potential breakthrough for the treatment of Alzheimer’s patients • High unmet medical need for disease-modifying treatments of Alzheimer’s disease • Short-term goal to initiate the first oligomer-specific clinical trial with a therapeutic vaccine in patients by Q3 2
Slide 17: Capitalisation table, summary of shares and options
Capitalisation table, summary of shares and options Shareholders, as per 30 December 2021: Capitalization table (amounts in million SEK): Market cap, as per 30 Dec. 2021 101.6 Subscription warrants TO 2020/2022 (SEK 8,75 WAEP) 2.) 35.6 Share options incentive program 2020/2023 (SEK 22,50 WAEP) 3.3 T
Slide 18: Thank you!
alzinova® Thank you!